B37.7 Candidal sepsis

Name of the Condition

• Candidal Sepsis (ICD Code: B37.7)
• Technical term: Candidal sepsis
• ICD-10 Code: B37.7

Summary

Candidal sepsis is a systemic fungal infection caused by Candida species, characterized by the presence of Candida in the bloodstream (fungemia) and associated with signs of systemic inflammation. It occurs when Candida, a normally commensal organism, overgrows and disseminates, leading to infection of internal organs. The condition is a severe manifestation of invasive candidiasis and requires prompt medical intervention.

Causes

Candidal sepsis results from the hematogenous spread of Candida species, typically Candida albicans, from a localized infection site (e.g., gastrointestinal tract, urinary tract, or intravenous catheter) into the bloodstream. This overgrowth is often triggered by disruptions to the body's microbial balance, impaired immune function, or invasive medical procedures that introduce the fungus into the vascular system.

Risk Factors

• Weakened immune system (e.g., chemotherapy, HIV/AIDS, organ transplantation).
• Prolonged use of broad-spectrum antibiotics or corticosteroids.
• Indwelling medical devices (e.g., central venous catheters, urinary catheters).
• Major surgery or trauma.
• Diabetes mellitus or poorly controlled blood sugar.
• Total parenteral nutrition (TPN) or prolonged hospitalization in intensive care units.

Symptoms

• Fever or hypothermia.
• Chills or rigors.
• Tachycardia or hypotension.
• Altered mental status or confusion.
• Shortness of breath or respiratory distress.
• Skin manifestations (e.g., petechiae, purpura, or erythematous rash).

Diagnosis

Diagnosis involves clinical evaluation of systemic signs of infection and laboratory confirmation. Blood cultures are the primary diagnostic tool, though they may have low sensitivity. Additional tests, such as serum (1,3)-β-D-glucan or Candida antigen assays, may support the diagnosis. Imaging (e.g., CT scans) may identify organ involvement (e.g., endophthalmitis, hepatosplenic candidiasis).

Treatment Options

Treatment includes antifungal therapy, typically with echinocandins (e.g., caspofungin) or fluconazole, depending on susceptibility and patient factors. Removal of infected medical devices is critical. Supportive care, such as hemodynamic stabilization and source control, is essential. Duration of therapy varies based on infection severity and resolution of symptoms.

Prognosis and Follow-Up

Prognosis depends on early intervention, underlying health status, and organ involvement. Mortality rates remain significant, particularly in immunocompromised patients. Follow-up includes monitoring for treatment response, repeat blood cultures, and assessment for complications (e.g., endocarditis, meningitis). Long-term surveillance may be needed for recurrent infections.

Complications

• Septic shock or multiorgan failure.
• Endocarditis or meningitis.
• Disseminated candidiasis (e.g., hepatosplenic, renal, or ocular involvement).
• Persistent fungemia despite treatment.
• Recurrent infections due to immunosuppression.

Lifestyle & Prevention

• Maintain good hygiene and skin integrity to reduce infection risk.
• Manage chronic conditions (e.g., diabetes) to optimize immune function.
• Promptly address localized Candida infections (e.g., urinary tract, wound infections).
• Minimize use of indwelling devices when possible; ensure proper care if used.
• Follow healthcare provider guidance for prophylactic antifungals in high-risk settings.

When to Seek Professional Help

Seek immediate medical attention if experiencing symptoms of systemic infection (e.g., fever, chills, confusion) or if a known Candida infection worsens. Prompt evaluation is critical for suspected sepsis, especially in immunocompromised individuals or those with indwelling devices.

Tips for Medical Coders

Document the presence of fungemia, systemic inflammatory response, and organ involvement to support the diagnosis. Include details on culture results, antifungal therapy, and any associated complications. Ensure documentation aligns with clinical findings to justify the specificity of B37.7 for candidal sepsis.